BRAF and melanoma: Since CDH23 mutations may coexist with BRAF or NRAS mutations, in future studies it would be interesting to analyse if the presence of CDH23 mutations could alter overall survival in BRAF or NRAS mutated melanoma patients, as it may lower patient overall survival and account for BRAF and NRAS resistance.